Merck KGaA (MKKGY) Stock Price, News & Analysis

Company Overview

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Key Stats

• Today's Range: $24.99 to $25.49
• 50-Day Range: $24.53 to $26.84
• 52-Week Range: $24.32 to $39.17
• Volume: 569,158 shs
• Average Volume: 142,401 shs
• Market Capitalization: $16.41 billion
• P/E Ratio: 10.67
• Dividend Yield: 1.34%
• Price Target: N/A
• Consensus Rating: Buy

Merck KGaA Stock Analysis - MarketRank™

Merck KGaA scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Merck KGaA.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 9.63%

Earnings Growth

Earnings for Merck KGaA are expected to grow by 9.63% in the coming year, from $1.87 to $2.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merck KGaA is 10.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merck KGaA is 10.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.98.

Price to Earnings Growth Ratio

Merck KGaA has a PEG Ratio of 1.96. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Merck KGaA has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the outstanding shares of Merck KGaA have been sold short.

Short Interest Ratio / Days to Cover

Merck KGaA has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Merck KGaA has recently increased by 26.16%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Merck KGaA pays a meaningful dividend of 1.38%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Merck KGaA does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Merck KGaA is 16.11%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Merck KGaA will have a dividend payout ratio of 16.59% next year. This indicates that Merck KGaA will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.02% of the outstanding shares of Merck KGaA have been sold short.

Short Interest Ratio / Days to Cover

Merck KGaA has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Merck KGaA has recently increased by 26.16%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.43

News Sentiment

Merck KGaA has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Merck KGaA this week, compared to 4 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Merck KGaA insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.10% of the stock of Merck KGaA is held by institutions.

MKKGY Stock Analysis - Frequently Asked Questions

How have MKKGY shares performed this year?

Merck KGaA's stock was trading at $28.63 at the beginning of 2025. Since then, MKKGY stock has decreased by 11.3% and is now trading at $25.39.

How were Merck KGaA's earnings last quarter?

Merck KGaA (OTCMKTS:MKKGY) released its quarterly earnings data on Thursday, August, 7th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.06. The business earned $6.11 billion during the quarter, compared to the consensus estimate of $5.34 billion. Merck KGaA had a trailing twelve-month return on equity of 9.81% and a net margin of 13.49%.

How do I buy shares of Merck KGaA?

Shares of MKKGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MKKGY
• Previous Symbol: OTCMKTS:MKKGY
• CIK: N/A
• Web: www.merckgroup.com
• Phone: 496151720
• Fax: 49-61-5172-2000
• Employees: 62,557
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $2.11
• Trailing P/E Ratio: 10.67
• Forward P/E Ratio: 13.58
• P/E Growth: 1.96
• Net Income: $3.00 billion
• Net Margins: 13.49%
• Pretax Margin: 16.86%
• Return on Equity: 9.81%
• Return on Assets: 5.73%

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 1.31
• Quick Ratio: 0.83

Sales & Book Value

• Annual Sales: $22.57 billion
• Price / Sales: 0.73
• Cash Flow: $8.44 per share
• Price / Cash Flow: 3.01
• Book Value: $50.22 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 646,210,000
• Free Float: N/A
• Market Cap: $16.41 billion
• Optionable: Not Optionable
• Beta: 0.91